Bioprocessing Application Notes & Case Studies

51. Implementing A Versatile Mixing System To Drive Down Costs 10/29/2025

    Learn how a CDMO reduced capital expenses and operational complexity by adopting an all-in-one mixing solution that supports every stage of production and a wide range of volumes.

52. Enhancing CRISPR Knock-In And Knock-Out 10/29/2025

    Achieve scalable, non-viral CRISPR delivery for T cells. The next-generation electroporation platform provides robust, efficient gene editing in large-scale volumes.

53. Cytokines For Ex Vivo Cell Culture 10/29/2025

    Comparable T cell expansion and function between cytokine sources were demonstrated. Generated CAR-T cells showed robust cytotoxicity and lower exhaustion markers.

54. In Vitro Drug Screening On Cancer Cells 10/29/2025

    Explore a high-throughput assay combining stain-free imaging and multiplexed viability/toxicity measurements to evaluate drug effects on cancer cells, ideal for labs optimizing cell-based screening.

55. Walk-Away Monitoring Of Cytotoxicity, Viability, And Apoptosis 10/29/2025

    Real-time cell health monitoring reveals how drug dose and timing impact apoptosis, necrosis, and viability. Explore how automated workflows help pinpoint mechanistic toxicity windows.

56. Getting The Most Out Of Cell-Based Assays With The Optimal Read Function 10/29/2025

    Gain insight into a whole-well fluorescence analysis that improves sensitivity and reproducibility in cell-based assays by accounting for uneven cell distribution.

57. Partner Case Study: Accelerating Gene Editing Manufacturing 10/28/2025

    Beam Therapeutics partnered with ElevateBio to manufacture BEAM-101, a novel base editing therapy for sickle cell disease, advancing rapid, high-quality production towards clinical trials.

58. In Vivo RNA Tuning for Liver Gene Editing Efficiency 10/28/2025

    RNA sequence and guide modifications, delivery platform design, and dose optimization all contribute to improved gene editing outcomes, which offers a clearer path toward safer, more potent, and scalable mRNA-based therapeutics.

59. Streamlining Analytical Release Testing With Faster, Smaller Workflows 10/28/2025

    Reducing turnaround times and sample volumes in release testing can accelerate cell therapy manufacturing, preserve product yield, and improve patient outcomes.

60. Advanced Sequencing Approaches For Comprehensive AAV Vector Characterization 10/28/2025

    Short and long read sequencing offer complementary insights into AAV vector identity, integrity, and impurity profiles, helping developers improve safety, efficacy, and scalability of gene therapy products.